Standing on the Shoulders of Giants

Abstract

The development of hemoglobin-based oxygen carriers (HBOCs) is usually told as a history of molecules, clinical trials and regulatory setbacks. This Historical Perspective examines another dimension: the people and institutional capabilities required to convert an oxygen-carrying concept into a manufactured, regulated and clinically used product. Biopure Corporation provides an unusual case. Around co-founder and process engineer Carl W. Rausch emerged a network that included industrialist David N. Judelson; physician-scientist and former National Heart Institute director Theodore Cooper; former U.S. Surgeon General C. Everett Koop; hospital and pharmaceutical leader Charles A. Sanders; and B. Braun research and technology executive Joachim Schnell. Their backgrounds spanned process chromatography, industrial scale-up, cardiovascular science, government, public health, hospital medicine, pharmaceutical development and clinical-delivery infrastructure. This convergence mattered because Biopure's challenge was larger than designing a hemoglobin molecule. It required control of a bovine biological source, purification and polymerization at pharmaceutical scale, pathogen and transmissible-spongiform-encephalopathy risk management, validated manufacturing, clinical development, regulatory engagement and commercialization. By 2002, this institutional platform had produced an FDA- and European-authorized veterinary oxygen therapeutic, advanced Hemopure through human clinical development and South African authorization, and brought a U.S. Biologics License Application to formal FDA review. The subsequent scientific, regulatory and corporate history was complex. Nevertheless, Biopure demonstrated that an oxygen therapeutic could travel from biological source to industrial process, regulated product and real clinical use. The central historical achievement was therefore not the molecule alone, but the coalition of people and capabilities that carried it across those boundaries.

Keywords: Biopure; Carl W. Rausch; Hemopure; Oxyglobin; hemoglobin-based oxygen carriers; HBOC; oxygen therapeutics; biotechnology history; biologics manufacturing; institutional leadership.

1. Introduction

Some biotechnology stories begin with a molecule. The story of Biopure begins with a problem:

How can oxygen-carrying capacity be provided when red blood cells cannot supply the required function at the required place and time?

In the 1980s, this question acquired new urgency. HIV/AIDS had transformed the public perception of transfusion. Blood remained indispensable medicine, but it could no longer be regarded as biologically simple or automatically safe. Evidence of transfusion-associated AIDS accumulated before a specific screening assay became available in 1985, creating a crisis of safety, institutional decision-making and public trust.1,2

The resulting search for alternatives attracted major pharmaceutical companies, biotechnology ventures, government researchers and academic laboratories. Yet the field discovered that carrying oxygen was only the beginning. Cell-free hemoglobin interacted with vascular physiology in ways that were not equivalent to hemoglobin enclosed within a red blood cell. Development programs failed, clinical results disappointed, safety concerns emerged and regulatory scrutiny intensified.3,4

Biopure continued through this increasingly difficult environment. Its history is important not because it was an uninterrupted success—it was not—but because it connected more parts of the translational chain than most programs in the field. This article argues that the company's distinguishing asset was not only its technology. It was the unusual combination of people capable of moving the technology from science to manufacturing, regulation and clinical use.

This is a historical perspective rather than a systematic review or a modern benefit-risk assessment. It prioritizes contemporaneous regulatory records and corporate filings, followed by institutional archives and peer-reviewed literature. Statements originating in Biopure materials are treated as company-reported historical evidence when independent confirmation is unavailable.

2. The People Who Made Biopure Different

By biotechnology-industry standards, the group assembled around Biopure was unusual. These were not individuals searching for the first important line on their résumés. Most had already led institutions large enough to define an entire career.

Their importance was not ceremonial. Each represented a capability that the oxygen-therapeutics problem required.

Table 1. The institutional capabilities assembled around Biopure

2.1. Carl W. Rausch: The Integrating Figure

At the center was Carl W. Rausch, Biopure's co-founder, long-serving Chairman and Chief Executive Officer, and later Chief Technology Officer. Before Biopure, Rausch worked in preparative and process chromatography at the Waters Associates division of Millipore. His earlier work involved developing process-scale chromatographic separation capability for industrial use—a background directly relevant to the challenge Biopure would later confront.5,6,17

This detail matters. Biopure was not simply trying to discover whether hemoglobin could carry oxygen; nature had already answered that question. The central industrial challenge was whether large quantities of biological material could be purified, modified, standardized and reproduced under pharmaceutical conditions.

Rausch's role therefore extended beyond that of a conventional biotechnology founder. His career connected the molecule to the process. Biopure's filings describe proprietary purification and polymerization systems, specialized large-scale equipment and computer-controlled manufacturing operations.5,6 Those capabilities did not arise from a single scientific insight. They required years of engineering judgment, organizational continuity and the ability to retain multiple disciplines around the same objective.

There is also a quieter leadership achievement. Around Rausch, Biopure assembled people whose careers came from very different worlds. The precise history of those introductions deserves first-person documentation rather than speculation. The composition of the group, however, is already evidence of an unusual capacity to make a technically difficult proposition credible to industrial, medical and public-health leaders.

2.2. David N. “Jim” Judelson: Industrial Scale

David N. Judelson brought a radically different background. He had co-founded Gulf & Western Industries and served as its President and Chief Operating Officer from 1967 to 1983. The major conglomerate included Paramount Pictures. Judelson was also a mechanical engineer.14

He became a co-founder and Vice Chairman of Biopure. The transition—from constructing one of America's best-known industrial conglomerates to supporting a biotechnology company in Cambridge—appears surprising only if biotechnology is viewed as laboratory science alone.

A scientific discovery does not automatically become an organization. It needs capital, structure, negotiation, facilities, management and the ability to survive the long distance between an experiment and a market. Judelson represented industrial imagination: the belief that a technically difficult process could be organized, financed and scaled into a real enterprise.

His relevance was therefore not that entertainment and biotechnology were similar industries. It was that both demanded the construction of systems larger than any single product or individual. Biopure needed someone who could think in terms of institutions, not merely experiments.

2.3. Theodore Cooper and Upjohn: Science, Government and Big Pharma

Theodore Cooper, M.D., Ph.D., moved through almost every institution capable of shaping modern medicine. He was a heart surgeon and cardiovascular researcher whose work included cardiac transplantation, artificial hearts, ventricular function and myocardial infarction. From 1968 to 1974 he directed the National Heart Institute during a period of substantial growth. He later held senior federal health roles, became Provost for Medical Affairs and Dean of Cornell University Medical College, and ultimately served as Chairman and Chief Executive Officer of The Upjohn Company.8

Biopure's historical relationship with Upjohn placed its technology in contact with a major pharmaceutical organization during Cooper's leadership. The significance went beyond capital. Cooper understood cardiovascular physiology, biomedical research, federal institutions, academic medicine and pharmaceutical development. Few careers integrated all five.

For an oxygen therapeutic, this combination was particularly relevant. The product could not be evaluated as chemistry alone. It had to be understood simultaneously as a cardiovascular intervention, a biologic, a clinical-development program, a manufacturing system and a regulated medicine. Cooper's career embodied that entire institutional pathway.

2.4. C. Everett Koop: Public Health and Trust

C. Everett Koop, M.D. was already one of America's most recognizable physicians when he joined Biopure's Board. A pioneering pediatric surgeon, he served as U.S. Surgeon General from 1981 to 1989 and became closely associated with the national response to AIDS.9

Koop was not at Biopure to design chromatography columns or polymerization chemistry. His presence represented another requirement: the intersection of medicine, biological risk, government and public trust.

That was not peripheral to the technology. Oxygen therapeutics had gained urgency partly because transfusion-transmitted infection had altered how society understood blood. Biopure then faced a second source-related fear because its hemoglobin was bovine. A company working in this environment needed more than technical confidence. It needed to understand why the public and regulators would ask difficult questions, and why credible answers had to be demonstrated rather than asserted.

Koop's participation should not be treated as evidence of clinical efficacy; board membership is not a scientific endpoint. Historically, however, it shows that a physician who had spent years confronting AIDS, surgery, public controversy and national health policy considered the project serious enough to join its governance.6,9

2.5. Charles A. Sanders: From the Hospital to Pharmaceutical Leadership

Charles A. Sanders, M.D. brought yet another institutional trajectory. A cardiologist, he served as General Director of Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He later became Vice Chairman of Squibb and Chairman and CEO of Glaxo Inc.15

Sanders joined Biopure's Board and later became Chairman.6 His career joined the places where new medicines are conceived, tested, administered and commercialized: the academic medical center, the hospital, the pharmaceutical company and the boardroom.

This was highly relevant to Biopure. A manufacturing team may create a consistent biologic, but clinical adoption requires physicians to understand when it should be used, what it can and cannot do, and how it fits into existing care. Sanders understood both the clinician's world and the industrial systems required to deliver a pharmaceutical product into that world.

His presence also sharpened the historical question. Why would a physician who had already led Massachusetts General Hospital and Glaxo choose to chair a relatively small company pursuing one of biotechnology's most controversial challenges? The documentary record establishes the decision; his personal reasoning should eventually be captured through direct testimony or archival research.

2.6. Joachim Schnell and B. Braun: The Path to the Clinician's Hand

Joachim Schnell, Ph.D. spent nearly four decades at B. Braun. He joined the company as a scientist, became head of research and development, entered its Management Board in 1971 and later held responsibility for research and technology, pharmaceuticals, Medical, Hospital Care and international operations. He also served for many years as Deputy Chairman of the Management Board.16

Through Schnell and B. Braun, a different form of expertise entered the Biopure story: not only pharmaceutical development, but the infrastructure through which medicine actually reaches hospitals—infusion systems, clinical products, manufacturing, distribution and European operations.

That distinction is important. Translational biotechnology does not end when a molecule works or when a regulator reviews a dossier. The final product must be manufactured, packaged, distributed, stored and placed into a clinician's hand in a form that can be used safely. B. Braun understood that last mile better than most organizations.

Historical Biopure materials describe an early relationship with B. Braun and Schnell's representation in the company's institutional network. His documented B. Braun career nevertheless makes clear what expertise he represented: the connection between technical development and the practical operating environment of hospital medicine.

3. An Unusual Convergence of Expertise

Seen individually, each biography is impressive. Seen together, they reveal the architecture of the problem.

Biopure needed someone who understood hemoglobin and someone who understood industrial purification. It needed manufacturing, capital and corporate endurance. It needed knowledge of cardiovascular physiology, clinical trials and regulatory institutions. It needed hospital experience, pharmaceutical development, infusion infrastructure, international operations and public trust.

No single person could supply all of those capabilities. The group mattered because its expertise was complementary rather than repetitive.

This was not a collection of famous names arranged around a speculative idea. The technology demanded precisely the kinds of institutions they had led. Rausch represented the process and the continuity of the platform. Judelson represented industrial scale. Cooper connected cardiovascular science, government, academia and Big Pharma. Koop represented medicine under conditions of public-health risk. Sanders bridged the hospital and the pharmaceutical enterprise. Schnell and B. Braun represented the route from manufacturing to clinical delivery.

Their biographies do not prove that every strategic decision was correct. They demonstrate something different: highly experienced people from distinct institutional worlds recognized that the oxygen-therapeutics problem was serious enough to justify their involvement.

4. The Technology in Brief: From Bovine Blood to Biologic

The technological history is essential, but it can be stated more simply.

Hemoglobin carries oxygen efficiently inside the red blood cell. Outside that cellular architecture, it behaves differently. A viable product therefore required far more than extraction. The source material had to be controlled; cellular debris and unwanted proteins removed; hemoglobin purified, chemically modified and polymerized; molecular characteristics and oxygen affinity maintained within specification; pathogens addressed; sterility assured; and the finished formulation reproduced lot after lot.5,6

Biopure's process used bovine red cells as the starting material and incorporated washing, filtration, diafiltration, high-performance liquid chromatography, polymerization, fractionation, formulation and sterile filling. The company's filings describe proprietary and patented purification and polymerization processes and production equipment designed for industrial operation.5,6

The bovine source created both an opportunity and a burden. It offered a potentially scalable raw-material supply, but it also required control of animal origin, health status and transmissible-spongiform-encephalopathy risk. Biopure described controlled sourcing and manufacturing steps validated for pathogen removal. The biological origin did not disappear; it had to be governed by the process.

The scale of the protein requirement made the industrial challenge unusual. Many biologics are administered in milligram quantities. Oxygen transport requires grams of hemoglobin, potentially repeated across multiple units. By 2002, Biopure reported validated annual manufacturing capacity of approximately 75,000 Hemopure units, installed equipment intended to support expansion toward 100,000 units and plans for a facility designed around 500,000 units annually.6

That is the technology story in its most relevant form:

Biological source → controlled process → standardized biologic → validated manufacturing → clinical product.

The importance lies not in the length of the manufacturing description, but in the fact that Biopure crossed each boundary.

5. Regulatory and Clinical Translation

5.1. Oxyglobin

In 1998, the FDA approved Oxyglobin® for the treatment of anemia in dogs.7 European authorization followed in 1999.5,6 The product was manufactured, distributed and used in veterinary practice.

By 2002, Biopure reported sales of more than 115,000 Oxyglobin units.6 Following a manufacturing shutdown associated with plant expansion and revalidation, the company also reported substantial backorders. The precise commercial scale was modest compared with mass-market pharmaceuticals, but the historical boundary was important: a bovine-derived, intravenously administered, polymerized hemoglobin oxygen therapeutic had moved from laboratory research through regulatory assessment into repeat commercial use.

5.2. Hemopure

The human pathway was more difficult. By 2002, Biopure reported more than 20 clinical trials, with 806 patients receiving Hemopure and additional compassionate-use experience.6 Published surgical studies examined tolerability, dose exposure and allogeneic-blood use.12

South Africa granted marketing authorization in 2001 for acutely anemic adult surgical patients, for the purpose of eliminating, reducing or delaying the need for allogeneic red-cell transfusion.5,6 Later clinician guidance described the South African experience while emphasizing that HBOC-201 was not equivalent to red cells and required careful clinical management.13

Biopure submitted a U.S. Biologics License Application in July 2002. The company reported that the submission contained more than 500,000 pages of clinical, preclinical and manufacturing documentation. On October 1, 2002, the FDA accepted the application for review.6

Acceptance was not approval. That distinction is essential. Yet in a field marked by abandoned programs and increasing skepticism, formal BLA review showed how far the combined scientific, manufacturing and institutional platform had travelled.

6. Discussion: Leadership as Part of the Technology

Biotechnology history often separates the molecule from the organization that carries it. Biopure shows why that separation can be misleading.

Its purification system was technology. Its validated manufacturing plant was technology. But so was the institutional architecture that connected engineers, physicians, industrialists, regulators, hospital leaders and pharmaceutical organizations. Without that architecture, the molecule would have remained an experiment.

The central role of Carl Rausch becomes clearer in this shorter interpretation. His achievement was not merely co-inventing or managing a product. It was maintaining continuity across domains that normally operate separately. Around that technical core, other leaders supplied the forms of credibility and competence required at successive boundaries.

This interpretation also changes the meaning of “standing on the shoulders of giants.” The giants were not distant historical figures whose discoveries could simply be cited. Some were present in the company, choosing to place their experience behind a technology whose outcome remained uncertain.

Their involvement should not be romanticized. Distinguished boards cannot eliminate physiological risk, guarantee regulatory success or rescue an unsustainable business model. Later evidence syntheses identified cardiovascular safety signals across the heterogeneous HBOC class and intensified scrutiny of product design and clinical-trial interpretation.4,10,11 Biopure later faced serious regulatory, financial and corporate difficulties.

Nevertheless, those later difficulties do not erase the translational sequence already achieved:

concept → process → validated manufacturing → clinical trials → regulatory authorization → commercial product → clinical use.

Few biotechnology programs travel the entire distance.

7. Historical Significance and Limitations

This perspective evaluates a technological, institutional and translational achievement. It does not claim that every clinical hypothesis advanced for HBOCs was validated. Regulatory authorization, BLA acceptance, manufacturing scale, product sales and clinical efficacy are distinct evidentiary categories. None should be substituted for a modern assessment of benefit-risk in a specific indication.

The historical record is also asymmetrical. Annual reports and SEC filings provide detailed evidence about manufacturing, regulatory milestones, clinical-program scale and formal leadership roles, but they naturally present the company's contemporary position. The personal pathways through which these individuals became involved are incompletely documented. Assertions about private motives have therefore been avoided.

The next stage of historical research should prioritize oral histories and original agreements. In particular, the relationship-building role of Carl Rausch, the origins of the Upjohn and B. Braun relationships, and the reasons Koop, Sanders, Judelson and others committed their time deserve to be recorded by people who were present. That history should not be reconstructed from admiration when it can still be established from evidence.

8. Conclusion

Biopure's history is not simply the history of a hemoglobin solution. It is the history of what was required to make that solution real.

Rausch brought process engineering and continuity. Judelson brought the logic of industrial construction. Cooper connected cardiovascular science, government, academia and Big Pharma. Koop brought the perspective of surgery, public health and trust. Sanders connected hospital medicine with pharmaceutical leadership. Schnell and B. Braun represented the systems through which a product moves from manufacturing into clinical practice.

Together, they formed something more consequential than an impressive board. They formed an institutional bridge across the boundaries that usually stop biotechnology: from discovery to process, from process to scale, from scale to regulation and from regulation to use.

Years passed. Experiments became processes. Processes became manufacturing. Manufacturing produced clinical material. Clinical material entered trials. One product became an approved veterinary medicine. Another reached human authorization and formal U.S. regulatory review.

Eventually, the product left the building.

Somewhere far from the boardroom, a clinician opened a package. At that moment, there was no Chairman, CEO, Surgeon General, pharmaceutical executive, industrialist or biotechnology founder.

There was only a patient—and oxygen that needed to reach tissue.

Perhaps that was the point all along.

9. References

1. Institute of Medicine (US) Committee to Study HIV Transmission Through Blood and Blood Products. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington, DC: National Academies Press; 1995. NCBI Bookshelf.

2. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion. 1991;31(1):4-11. doi:10.1046/j.1537-2995.1991.31191096183.x.

3. Chen JY, Scerbo M, Kramer G. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo). 2009;64(8):803-813. doi:10.1590/S1807-59322009000800016.

4. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19):2304-2312. doi:10.1001/jama.299.19.jrv80007.

5. Biopure Corporation. Annual Report 2001. Cambridge, MA: Biopure Corporation; 2002. Relevant archival PDF pages: 3-6, 20-21, 27, 39 and 59. Primary archival document.

6. Biopure Corporation. Annual Report 2002. Cambridge, MA: Biopure Corporation; 2003. Relevant archival PDF pages: 6, 13-16, 18, 26, 32 and 48. Primary archival document.

7. U.S. Food and Drug Administration, Center for Veterinary Medicine. Freedom of Information Summary: Original Approval, NADA 141-067, Oxyglobin (hemoglobin glutamer-200 [bovine]). 1998. FDA record.

8. National Heart, Lung, and Blood Institute. Theodore Cooper: NHLBI Director, 1968-1974. National Institutes of Health. Institutional biography.

9. U.S. National Library of Medicine. C. Everett Koop Papers, 1933-2011. History of Medicine Division, Archives and Modern Manuscripts Collection; MS C 489. Archival finding aid.

10. Winslow RM. Cell-free oxygen carriers: scientific foundations, clinical development, and new directions. Biochim Biophys Acta. 2008;1784(10):1382-1386. doi:10.1016/j.bbapap.2008.04.032.

11. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nature Medicine. 2003;9(5):496-500. doi:10.1038/nm0503-496.

12. Sprung J, Kindscher JD, Wahr JA, et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesthesia & Analgesia. 2002;94(4):799-808. doi:10.1097/00000539-200204000-00006.

13. Mer M, Hodgson E, Wallis L, et al. Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients. Transfusion. 2016;56(10):2631-2636. doi:10.1111/trf.13726.

14. Biopure Corporation. Definitive Proxy Statement. U.S. Securities and Exchange Commission; 2008. David N. Judelson biographical disclosure. SEC filing.

15. The Commonwealth Fund. Charles A. Sanders, M.D.: Board of Directors Chair, 1993-2002. Institutional biography.

16. B. Braun. B. Braun trauert um Dr. Joachim Schnell. 2023. Corporate historical record.

17. The Wall Street Transcript. Carl W. Rausch: Biopure Corporation executive biography and interview record. 2000. Biographical record.

Copyright and Permissions

© 2026 Archil Jaliashvili. All rights reserved.

The original text, structure and editorial synthesis of this article are protected by copyright. Citation and linking with clear attribution are encouraged. Reproduction, republication, translation, adaptation or commercial use requires the prior written permission of the author. Copyright does not extend to third-party publications, public records or archival materials cited in the References; those materials remain subject to their respective rights and terms.

Article prepared August 2026

Archil Jaliashvili